Results 61 to 70 of about 53,097 (209)
Non-Hodgkin's lymphoma in a chronic myelocytic leukemia patient treated with imatinib
Turkish Journal of Hematology, 2011 Imatinib is an important example of tyrosine kinase inhibitors (TKIs) used in clinical practice. Imatinib blocks the ATP binding site of the Bcr-Abl fusion protein and selectively inhibits Bcr-Abl tyrosine kinase (TK) activity.
Semra Paydaş +2 more
doaj +3 more sources
Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
Journal of Community Hospital Internal Medicine Perspectives, 2018 Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation ...
Adnan Asif Parvez Ghias +3 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo +10 more
wiley +1 more source
International Journal of Cancer, EarlyView.Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel +26 more
wiley +1 more source
Journal of Applied Toxicology, EarlyView.ABSTRACT In this study, ten novel compounds (IPH1–IPH10) were designed by integrating three pharmacophores (isatin, piperazine, and hydrazone) commonly found in the molecular structures of anticancer agents. The target molecules were obtained by the reaction of in‐house prepared 4‐(4‐(pyridin/pyrimidin‐2‐yl)piperazin‐1‐yl)benzohydrazide with various ...
Semiha Köprü +3 more
wiley +1 more source
Journal of Surgical Oncology, EarlyView.ABSTRACT Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. We conducted a systematic review and meta‐analysis of studies that developed, validated, or updated clinical prognostic tools to predict survival in adults with primary GIST, identifying 47 eligible studies (38 development and 9 ...
Alice Zhu +7 more
wiley +1 more source
Journal of Translational MedicineBackground Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal sarcomas of the upper digestive tract. Imatinib is the first-line therapy for patients with metastatic or unresectable GISTs.
Hanxing Tong +8 more
doaj +1 more source
Proteomes, 2014 Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases.
Katerina Arvaniti +5 more
doaj +1 more source
Journal of Surgical Oncology, EarlyView.ABSTRACT Sarcomas represent a diverse group of mesenchymal tumors with high rates of recurrence after resection. While recent technical advances have enabled the detection of rare circulating tumor DNA (ctDNA) in other malignancies, the complexity and heterogeneity of sarcoma genomics have historically limited ctDNA in these cancers.
Kristin E. Goodsell +5 more
wiley +1 more source
Nephrogenic Systemic Fibrosis: A Rare Contemporary Case After a Decade of Declining Incidence
JEADV Clinical Practice, EarlyView.ABSTRACT Nephrogenic systemic fibrosis (NSF) is a rare fibrosing disorder associated with exposure to gadolinium‐based contrast agents in patients with renal impairment. Although its incidence has markedly declined since the restriction of high‐risk linear gadolinium agents, sporadic cases may still occur.
Marta Sánchez Díaz +5 more
wiley +1 more source